Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

E Gerdts, G de Simone, Birthe Lund, P M Okin, K Wachtell, K Boman, M S Nieminen, B Dahlöf, R B Devereux

    26 Citationer (Scopus)


    BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p 
    TidsskriftNutrition, Metabolism & Cardiovascular Diseases
    Udgave nummer2
    Sider (fra-til)122-129
    StatusUdgivet - 2013


    Dyk ned i forskningsemnerne om 'Impact of overweight and obesity on cardiac benefit of antihypertensive treatment'. Sammen danner de et unikt fingeraftryk.